Results 161 to 170 of about 272,115 (210)

Unexplained long-term increase in intraocular pressure during the treatment of macular disease with intravitreal anti-VEGF. [PDF]

Graefes Arch Clin Exp Ophthalmol
Eisenrauch LM, Abu-Dail Y, Munteanu C, Flockerzi E, Seitz B, Abdin AD.   +5 more
europepmc   +1 more source

A Kinetic Study of anti-VEGF-A Polyclonal Antibodies and anti-VEGF-A ssDNA Aptamers

, 2016
openaire   +2 more sources

ANTI-VEGF TREATMENT Safety of intravitreal anti-VEGFs during pregnancy is unclear

, 2012
Georgalas, Ilias, Petrou, Petros, Koutsandrea, Chrysanthi   +2 more
openaire   +1 more source

Evaluation of Spectral Domain OCT Changes Following Anti-VEGF Therapy in Diabetic Macular Edema.

J Pharm Bioallied Sci
Mandloi G, Jain A, Sharma A, Tirkey ER, Jain S.   +4 more
europepmc   +1 more source

Anti-VEGF treatment for macular conditions

Community Eye Health Journal
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Anti-VEGF Treatment of Corneal Neovascularization

Ocular Surface, 2011
Vascular endothelial growth factor (VEGF) is an angiogenic factor shown to be a critical secreted cytokine in tumorigenesis and retinal neovascularization (NV). Currently, there are two anti-VEGF agents, pegaptanib and ranizumab, approved by the United States Food and Drug Administration (FDA) for intravitreal use in the treatment of wet age-related ...
Deborah S Jacobs
exaly   +3 more sources

New Anti-VEGF Drugs in Ophthalmology

Current Drug Targets, 2020
: This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. : Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
Claudio Campa
exaly   +3 more sources

Anti-VEGF and Retinal Dystrophies

Current Drug Targets, 2020
The therapeutic approach based on anti-vascular endothelial growth factor (anti-VEGF) molecules can be used to treat two important complications of retinal dystrophies: choroidal neovascularization and macular edema. The macular involvement in retinal dystrophies can lead to further visual deterioration in patients at a young age and already affected
Battaglia Parodi Maurizio, Iacono Pierluigi, Da Pozzo Stefano   +2 more
openaire   +3 more sources

Resistance to Anti-VEGF Agents

Current Pharmaceutical Design, 2004
The number of anti-angiogenic agents developed for clinical use has risen greatly over the past decade. Currently, more than 80 are in trials ranging from phase I through to phase III studies and many more are in preclinical evaluation. Much hope was envisaged for these new agents to become the panacea of anti-tumoural treatment.
Ton, N. C., Jayson, G. C.; id_orcid 0000-0002-8515-8944   +1 more
openaire   +2 more sources

Anti-VEGF therapy for glaucoma

Current Opinion in Ophthalmology, 2010
The role of antivascular endothelial growth factor (anti-VEGF) agents in treating various ophthalmic diseases is currently being investigated. There have been many advances in the understanding of how anti-VEGF agents work and speculation on when to implement them clinically for neovascular glaucoma.
Michael B, Horsley, Malik Y, Kahook
openaire   +2 more sources